Subscribe To
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Carlyle commodities reveals phase 2 drilling strategy at newton project in british columbia
Carlyle Commodities Corp (CSE:CCC, OTCQB:CCCFF) has outlined the Phase 2 drilling strategy at its 100% owned Newton Gold Project near Williams Lake, B...
October 19, 2023, 9:04 am
Pantheon resources to advance into field development as latest test validate new frac design
Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) chief executive Jay Cheatham highlighted that the company's three core ...
October 19, 2023, 3:52 am
Signal says don't sweat the airbnb stock pullback
Airbnb Inc (NASDAQ:ABNB) stock is down 1.9% to trade at $123.38 at last check, after Jefferies cut its price ...
October 18, 2023, 3:32 pm
Hipgnosis songs fund meeting to face objections from major shareholders
Analysts and a major investor say that the upcoming Hipgnosis Songs Fund Limited (LSE:SONG) shareholder meeting might echo the Ella Fitzgerald song ...
October 17, 2023, 9:56 am
Lyondellbasell (lyb) buys stake in plastic waste recycling firm
The investment in DPSR is in sync with LyondellBasell's (LYB) objective to enhance access to plastic wa...
October 17, 2023, 8:16 am
Wk kellogg's ‘soggy' market debut already priced in: analysts
WK Kellogg Co stock has suffered, falling more than 43%, since Kellogg spun out Kellanova, its snacks and other foods-focused division, into a separat...
October 16, 2023, 3:31 pm
Eu expansion objectives, advantages, challenges & prospects
The post EU Expansion objectives, Advantages, Challenges & Prospects appeared first on FinanceBrokerage...
October 16, 2023, 7:08 am
Outset medical analysts slash price objective after multiple missteps
Outset Medical Inc stock was downgraded by BofA Securities analysts to ‘Underperform' from ‘Buy', and its price ...
October 13, 2023, 3:42 pm
Statement by cassava sciences regarding an internal cuny report leaked to the press
CUNY’s report makes no findings of data manipulation. The “egregious misconduct” cited in the report relates to internal record-keeping failures...
October 13, 2023, 3:43 am
Microsoft gets uk green light for activision deal, but slammed for 'wasting time and money'
Microsoft Corporation (NASDAQ:MSFT)'s revised US$69 billion deal to buy video games maker Activision Blizzard Inc (NASDAQ:ATVI) has been given the gre...
October 13, 2023, 2:58 am